• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢阻肺作为死因的漏报严重——基于人群的队列研究结果。

Large underreporting of COPD as cause of death-results from a population-based cohort study.

机构信息

Department of Public Health and Clinical Medicine, Section of Medicine, Umeå University, Umeå, Sweden.

Krefting Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

出版信息

Respir Med. 2021 Sep;186:106518. doi: 10.1016/j.rmed.2021.106518. Epub 2021 Jun 24.

DOI:10.1016/j.rmed.2021.106518
PMID:34217049
Abstract

BACKGROUND

In 2019, WHO estimated COPD to be the third leading cause of death in the world. However, COPD is probably underestimated as cause of death due to the well-known under-diagnosis.

AIM

To evaluate the proportion of and factors associated with COPD recorded as cause of death in a long-term follow-up of a population-based COPD cohort.

METHODS

The study population includes all individuals (n = 551) with COPD defined as chronic airway obstruction (post-bronchodilator FEV/FVC<0.70) + respiratory symptoms identified after re-examinations of four population-based cohorts. Mortality and underlying or contributing cause of death following ICD-10 classification were collected from the Swedish National Board of Health and Welfares register from date of examination in 2002-04 until 2016.

RESULTS

The study sample consisted of 32.3% GOLD 1, 55.9% GOLD 2, and 11.8% GOLD 3-4. The mean follow-up time was 10.3 (SD3.77) years and the cumulative mortality 45.0%. COPD (ICD-10 J43-J44) was recorded on 28.2% (n = 70) of the death certificates (11.1%, 25.7% and 57.1% by GOLD stage), whereof n = 35 had COPD recorded as underlying and n = 35 as contributing cause of death. To have COPD recorded as cause of death was independently associated with ex- and current smoking and a self-reported physician diagnosis of COPD, while male sex, overweight/obesity and higher FEV% of predicted associated with the absence.

CONCLUSIONS

COPD was largely underreported cause of death. Even among those with severe/very severe disease, COPD was only mentioned on 57.1% of the death certificates.

摘要

背景

2019 年,世界卫生组织(WHO)估计 COPD 是全球第三大死亡原因。然而,由于众所周知的诊断不足,COPD 可能被低估为死亡原因。

目的

评估在一项基于人群的 COPD 队列的长期随访中,将 COPD 记录为死因的比例和相关因素。

方法

研究人群包括所有(n=551)经支气管扩张剂后 FEV/FVC<0.70 定义为慢性气道阻塞(COPD)+经四次人群队列复查后出现呼吸道症状的个体。死亡率和根据 ICD-10 分类的根本死因或促成死因,从瑞典国家卫生和福利委员会登记处从 2002-04 年的检查日期开始收集到 2016 年。

结果

研究样本由 32.3%的 GOLD 1 期、55.9%的 GOLD 2 期和 11.8%的 GOLD 3-4 期组成。平均随访时间为 10.3(SD3.77)年,累积死亡率为 45.0%。在 28.2%(n=70)的死亡证明上记录了 COPD(ICD-10 J43-J44)(GOLD 分期分别为 11.1%、25.7%和 57.1%),其中 n=35 例 COPD 被记录为根本死因,n=35 例 COPD 被记录为促成死因。将 COPD 记录为死因与既往和当前吸烟以及自我报告的 COPD 医生诊断独立相关,而男性、超重/肥胖和更高的 FEV%预测值与 COPD 不存在相关。

结论

COPD 是死因的主要漏报原因。即使在那些患有严重/非常严重疾病的患者中,也只有 57.1%的死亡证明提到了 COPD。

相似文献

1
Large underreporting of COPD as cause of death-results from a population-based cohort study.慢阻肺作为死因的漏报严重——基于人群的队列研究结果。
Respir Med. 2021 Sep;186:106518. doi: 10.1016/j.rmed.2021.106518. Epub 2021 Jun 24.
2
Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study.应用 2017 年新版全球慢性阻塞性肺疾病倡议分类标准预测慢性阻塞性肺疾病患者的死亡率:一项队列研究。
Lancet Respir Med. 2018 Mar;6(3):204-212. doi: 10.1016/S2213-2600(18)30002-X. Epub 2018 Jan 10.
3
Up-to-date on mortality in COPD - report from the OLIN COPD study.慢性阻塞性肺疾病死亡率最新报告——OLIN COPD 研究。
BMC Pulm Med. 2012 Jan 9;12:1. doi: 10.1186/1471-2466-12-1.
4
Severe COVID-19 among patients with asthma and COPD: a report from the Swedish National Airway Register.哮喘和 COPD 患者的严重 COVID-19:来自瑞典气道登记处的报告。
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049738. doi: 10.1177/17534666211049738.
5
Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study.丹麦一般人群中无症状和有症状、未经诊断的 COPD 的预后:一项前瞻性队列研究。
Lancet Respir Med. 2017 May;5(5):426-434. doi: 10.1016/S2213-2600(17)30119-4. Epub 2017 Apr 4.
6
Mortality of patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study.慢性阻塞性肺疾病患者的死亡率:一项全国范围内基于人群的队列研究。
Korean J Intern Med. 2019 Nov;34(6):1272-1278. doi: 10.3904/kjim.2017.428. Epub 2019 Oct 16.
7
Mortality Related to Chronic Obstructive Pulmonary Disease and Co-morbidities in the United States, A Multiple Causes of Death Analysis.美国慢性阻塞性肺疾病及其合并症相关死亡率:多死因分析
COPD. 2018 Apr;15(2):200-205. doi: 10.1080/15412555.2018.1454897. Epub 2018 Apr 26.
8
COPD-Related Mortality and Co-morbidities in Northeastern Italy, 2008-2012: A Multiple Causes of Death Analysis.2008 - 2012年意大利东北部慢性阻塞性肺疾病相关死亡率及合并症:多死因分析
COPD. 2016;13(1):35-41. doi: 10.3109/15412555.2015.1043427. Epub 2015 Sep 14.
9
An epidemiologic study of physician-diagnosed chronic obstructive pulmonary disease in the Turkish population: COPDTURKEY-1.一项针对土耳其人群中医生诊断的慢性阻塞性肺疾病的流行病学研究:COPDTURKEY-1。
Turk J Med Sci. 2020 Feb 13;50(1):132-140. doi: 10.3906/sag-1908-35.
10
Potential misclassification of causes of death from COPD.慢性阻塞性肺疾病(COPD)死亡原因的潜在错误分类。
Eur Respir J. 2006 Oct;28(4):781-5. doi: 10.1183/09031936.06.00152205. Epub 2006 Jun 28.

引用本文的文献

1
Risk of exacerbations, hospitalisation, and mortality in adults with physician-diagnosed chronic obstructive pulmonary disease with normal spirometry and adults with preserved ratio impaired spirometry in Sweden: retrospective analysis of data from a nationwide cohort study.瑞典肺功能正常的医生诊断为慢性阻塞性肺疾病的成年人以及肺功能比值受损但保留的成年人的急性加重、住院和死亡风险:一项全国性队列研究数据的回顾性分析
Lancet Reg Health Eur. 2025 May 14;54:101322. doi: 10.1016/j.lanepe.2025.101322. eCollection 2025 Jul.
2
All-cause and cause-specific mortality in individuals with COPD in China: a 16-year follow-up cohort study.中国慢性阻塞性肺疾病患者的全因死亡率和特定病因死亡率:一项16年随访队列研究。
Eur J Epidemiol. 2025 Jun 4. doi: 10.1007/s10654-025-01252-7.
3
The effects of various nutritional supplements in patients with chronic obstructive pulmonary disease: a network meta-analysis.多种营养补充剂对慢性阻塞性肺疾病患者的影响:一项网状Meta分析。
BMC Pulm Med. 2025 May 8;25(1):220. doi: 10.1186/s12890-025-03667-0.
4
All-cause and cause-specific mortality in respiratory symptom clusters: a population-based multicohort study.呼吸症状群中的全因死亡率和病因特异性死亡率:一项基于人群的多队列研究。
Respir Res. 2025 Apr 16;26(1):150. doi: 10.1186/s12931-025-03224-7.
5
Validation of new predictors of mortality and BODE index variants in patients with COPD at moderate altitude.中度海拔慢性阻塞性肺疾病患者死亡率新预测指标及BODE指数变体的验证
ERJ Open Res. 2025 Jan 27;11(1). doi: 10.1183/23120541.00333-2024. eCollection 2025 Jan.
6
Sex Differences in Impacts of Early Gestational and Peri-Adolescent Ozone Exposure on Lung Development in Rats: Implications for Later Life Disease in Humans.早期妊娠和青春期前臭氧暴露对大鼠肺发育影响的性别差异:对人类晚年疾病的启示。
Am J Pathol. 2024 Sep;194(9):1636-1663. doi: 10.1016/j.ajpath.2024.05.013.
7
Lung Transcriptomics Links Emphysema to Barrier Dysfunction and Macrophage Subpopulations.肺转录组学将肺气肿与屏障功能障碍及巨噬细胞亚群联系起来。
Am J Respir Crit Care Med. 2024 Jun 27;211(1):75-90. doi: 10.1164/rccm.202305-0793OC.
8
Perspectives of family caregivers and nurses on hospital discharge transitional care for Muslim older adults living with COPD: a qualitative study.家庭照顾者和护士对患有慢性阻塞性肺疾病的老年穆斯林患者出院过渡护理的看法:一项定性研究
BMC Nurs. 2024 Apr 24;23(1):273. doi: 10.1186/s12912-024-01943-8.
9
All-cause and cause-specific mortality by spirometric pattern and sex - a population-based cohort study.基于肺活量测定模式和性别的全因死亡率及特定病因死亡率——一项基于人群的队列研究
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241232768. doi: 10.1177/17534666241232768.
10
Single-cell immunophenotyping revealed the association of CD4+ central and CD4+ effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC.单细胞免疫表型分析揭示了 CD4+ 中央记忆和 CD4+ 效应记忆 T 细胞与加重慢性阻塞性肺疾病(COPD)和 NSCLC 的关联。
Front Immunol. 2023 Dec 20;14:1297577. doi: 10.3389/fimmu.2023.1297577. eCollection 2023.